By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
Distributed storage Answers for Information Reinforcement - 2Scientists document a death from a meat allergy tied to certain ticks
- 3Bahrain cracks down on dissent as war grinds on
- 4Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico
- 5Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- Find the Specialty of Public Speaking: Drawing in and Convincing Crowds with Certainty
- First Houthi launch toward Israel since war began triggers alerts across the Negev
- RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- Find Unexpected, yet invaluable treasure Excursion Rentals
- Genesis Marks 10th Anniversary With Magma GT Concept Aimed at High-Performance Flagships
- Iran-backed militias reassert power in Iraq, proving the Islamic axis is still standing
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
